A rare tumor that deserves more attention
Lung neuroendocrine tumors (LNETs) are a distinct and relatively uncommon type of lung cancer. They arise from specialized cells in the lung that are part of both the nervous system and the hormone-producing (endocrine) system. They behave differently from common lung cancers — often growing more slowly, though some subtypes can be aggressive.
Surgery is the primary treatment for LNETs when the tumor is localized. But the question of how much lung tissue to remove has never been well answered. Should surgeons take the entire lobe (the standard approach for most lung cancers) or can they get away with taking less?
The standard approach — and its trade-offs
For decades, the default in lung cancer surgery has been lobectomy — removing the entire lobe of the lung that contains the tumor. This approach has been favored because it ensures a wide margin around the tumor and allows thorough sampling of lymph nodes (the small glands that are checked to see if cancer has spread).
But removing an entire lobe carries real costs. Patients lose permanent lung function. Recovery is harder. For older patients or those with limited breathing capacity, a lobectomy can significantly reduce quality of life.
Sub-lobar resection — removing only a portion of the lobe — preserves more lung tissue. It comes in two forms: segmentectomy (removing one anatomical segment of the lobe) and wedge resection (cutting out a wedge-shaped piece of tissue without following anatomical boundaries). The two are not the same, and the difference turns out to matter a great deal.
How surgeons think about cutting
Think of the lung like a cluster of grapes. A lobectomy removes the entire cluster. A segmentectomy removes one grape along its natural stem — following the lung's own internal structure. A wedge resection cuts across the cluster at an angle, ignoring those natural boundaries.
The grape analogy explains why wedge resections are more controversial. By not following natural tissue planes, surgeons may get closer to the tumor edges and remove fewer lymph nodes — potentially leaving behind microscopic disease.
Researchers conducted a systematic review and meta-analysis — pooling data from six studies and 3,700 patients. Of those, about 2,400 underwent lobectomy and 1,300 had sub-lobar resection. They used statistical modeling to compare overall survival between the groups.
The pooled five-year survival rate across all patients was 78.8%. That's a meaningful benchmark for a cancer type that can vary widely in its behavior.
The finding that shifts the conversation
When comparing lobectomy to sub-lobar resection overall, researchers found no statistically significant difference in survival. The hazard ratio — a measure of relative risk — was 1.21 with a confidence interval spanning 0.80 to 1.83, meaning the data could not rule out chance as an explanation for the small observed difference.
But the picture changed sharply when sub-lobar procedures were separated. Segmentectomy matched lobectomy in survival outcomes (p = 0.38, meaning essentially no meaningful difference). Wedge resection, however, was associated with twice the risk of death compared to lobectomy.
This doesn't mean every patient with a lung neuroendocrine tumor should get a smaller surgery — the type of limited surgery matters enormously.
The study also found that lobectomy patients had more lymph nodes examined (an average of more than 10 vs. fewer than 8 in sub-lobar cases), and were more likely to be "upstaged" — meaning the cancer was found to have spread to lymph nodes that weren't suspected before surgery. This finding underscores that thorough lymph node assessment remains essential regardless of which operation is chosen.
What the surgical community is weighing
This analysis fills an important gap. For most lung cancers, the evidence strongly favors lobectomy over limited resection for curative intent. But LNETs are not most lung cancers. Their slower growth patterns and different biology may make them more forgiving of a less radical surgical approach — at least when that approach is a well-executed segmentectomy with adequate lymph node sampling.
If you or a family member has been diagnosed with a lung neuroendocrine tumor and surgery has been recommended, this research is relevant to your conversation with a thoracic surgeon. It suggests that in carefully selected patients, a segmentectomy may offer comparable survival to a full lobectomy — with better preserved lung function. Ask specifically about lymph node assessment plans and which type of limited resection would be performed. Not all sub-lobar surgeries are equal.
This meta-analysis combined only six studies, and the patient selection criteria varied across them. Patients who received sub-lobar resections may have had smaller or more favorable tumors to begin with, which could bias survival comparisons in favor of limited surgery. The confidence intervals on some estimates were wide, reflecting genuine uncertainty. Long-term survival data beyond five years was limited, and information on specific LNET subtypes (which range from low-grade typical carcinoids to aggressive large cell neuroendocrine carcinomas) was not always available.
This is described as the first meta-analysis on this specific question, and the authors are clear that it should not be the last. Prospective trials that randomly assign patients to lobectomy versus segmentectomy — with standardized lymph node protocols — are needed to confirm whether limited surgery is truly equivalent. As minimally invasive surgical techniques continue to improve, the question of how little is enough will only become more important for the patients facing these decisions.